A two-phase Phase 3 study of the safety and efficacy of Sativex®, in t
A two-phase Phase 3 study of the safety and efficacy of Sativex®, in the symptomatic relief of spasticity in subjects with spasticity due to multiple sclerosis: Phase A – single blind response assessment; Phase B - double blind, randomised, placebo controlled, parallel group study.
What was tested
Treatment tested
- Nabiximols
What it measured
Main measures
The primary endpoint is the mean spasticity NRS score over the last seven days of the evaluable period (end of treatment - usually week 17 in those subjects who demonstrated a response in Phase A.
Spasticity
Loading reviews and guidelines…
Related trials
- Cryoneurolysis to treat pain in the context of spasticity
Phase 4 · Ongoing (inferred)
Still running
- A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spas
Phase 3 · Not yet recruiting
Still running
- Cannabis (THC vs. CBD) in Multiple Sclerosis
Phase 2 · Recruiting
Still running
- Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pa
Phase 2 · Recruiting
Still running
- Antibiotic strategy and asymptomatic bacteriuria in the context of int
Phase 3 · Ongoing
Still running
- A study to asses the effects of Nabiximols on spasticity associated wi
Phase 3 · Completed
No results found
History
- In scope changed from true to false
Started
Jul 2007
Assembled by software from public sources.